Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07206264) titled 'Chemotherapy Combined With Targeted Therapy as First-line Treatment for Mantle Cell Lymphoma Based on MRD and PET-CT Assessment' on Sept. 25.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Tianjin Medical University Cancer Institute and Hospital

Condition: Mantle Cell Lymphoma

Intervention: Drug: Bendamustine + anti-CD20 monoclonal antibody/orelabrutinib + anti-CD20 monoclonal antibody

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: October 2025

Targ...